Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Invivyd, Inc. (IVVD)

Invivyd Q2 revenue rises 21% to $14.3 million; net loss widens to $44.4 million

Mixed Impact 4 of 5 earnings Written later

Invivyd reported second-quarter 2026 PEMGARDA net product revenue of $14.3 million, up 21% from $11.8 million a year earlier. Net loss grew to $44.4 million, or $0.14 per share, from $14.7 million, or $0.12 per share, as R&D and SG&A expenses rose sharply for the VYD2311 clinical trials and commercial activities, which matters to shareholders because the company's cash of $160.1 million is expected to fund operations through the DECLARATION pivotal data readout.

Key points

  • Q2 2026 R&D expenses were $29.4 million, up from $9.6 million, mainly from DECLARATION and LIBERTY trial costs.
  • Q2 2026 SG&A expenses were $29.5 million, up from $16.6 million.
  • Cash and cash equivalents were $160.1 million as of June 30, 2026.
  • In July 2026, Invivyd received twelve months' advance notice of the termination of the PEMGARDA emergency use authorization.

The filing

CompanyInvivyd, Inc. (IVVD)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:11 PM ET
Accession number0001193125-26-349193

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.